Understanding ALK Positive Lung Cancer
WHAT IS ALK+
ALK Positive cancer, first discovered in 2007, is a form of non-small lung cancer driven by a genetic alteration involving the rearrangement of the ALK gene (short for anaplastic lymphoma kinase) and often the EML4 gene.
This rearrangement creates a fusion oncogene called EML4-ALK, which results in abnormal cell signaling that leads to uncontrolled cell growth—essentially, cancer.
The ALK gene is a normal part of everyone’s DNA. This mutation is not inherited, and it has no known environmental cause. It simply happens—and scientists don’t know why.
While ALK Positive cancer can manifest in various organs, including the brain and breast, it is most commonly associated with lung cancer.
Who gets ALK+?
What sets ALK Positive lung cancer apart is that it tends to occur in people with no history of smoking. In fact, about half of all patients diagnosed with this subtype are under the age of 50, and the disease has no known environmental or hereditary causes. Unlike many other lung cancers, there is no clear link between ALK Positive lung cancer and exposure to toxins like tobacco smoke, asbestos, or air pollution. It is caused by a spontaneous mutation in the ALK gene, typically acquired during a person’s lifetime rather than inherited.
Globally, it’s estimated that ALK Positive lung cancer affects approximately 72,000 individuals each year. Unfortunately, because there are no effective early screening tools, the disease is often diagnosed at an advanced stage—typically stage III or IV—when treatment becomes more complex and outcomes are less favorable. Although it remains an incurable disease once it has metastasized, ongoing research continues to seek targeted therapies that can help manage and extend the lives of those affected.
Why It Matters More Than Ever
1
Lung cancer is also the second most common cancer in both women and men in the U.S., with a lifetime risk of about 1 in 17 for women and 1 in 16 for men.
2
ALK+ lung cancer deserves urgent attention because it affects thousands yearly, including many young, healthy non-smokers—and it responds well to targeted treatments that offer hope.
3
Yet lung cancer remains one of the least talked-about and least funded cancers—especially when it affects non-smokers.
4
New treatments are extending lives. Clinical trials are pushing boundaries. And with enough funding, a vaccine could be next.
Whether you’re a patient, a loved one, or someone ready to make a difference, you do have power to change the future of lung cancer.
Vaccines hold incredible promise to transform how we fight this disease—and save countless lives.
At Love4Lungs, we’re committed to making that future real. We fuel groundbreaking research, support innovative treatments, and raise bold awareness—together, lighting the path toward lasting breakthroughs.